国新健康保障服务集团股份有限公司 2024 年度募集资金年度存放与使用情况专项报告 根据中国证监会发布的《上市公司监管指引第 2 号——上市公司募集资金管 理和使用的监管要求》（证监会公告[2012]44 号）和深圳证券交易所发布的《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等有关 规定，国新健康保障服务集团股份有限公司（以下简称"公司"或"本公司"）董事 会编制了截至 2024 年 12 月 31 日止的募集资金年度存放与实际使用情况的专项 报告。 一、募集资金基本情况 中国证券监督管理委员会于 2023 年 8 月 23 日出具了《关于同意国新健康保 障服务集团股份有限公司向特定对象发行股票注册的批复》（证监许可〔2023〕 1899 号），同意公司向特定对象发行股票的注册申请。 公司本次向特定对象发行股票 80,413,268 股，发行价格为 9.88 元/股。根据 大信会计师事务所（特殊普通合伙）出具的《国新健康保障服务集团股份有限公 司向特定对象发行股票募集资金验资报告》（23-00006 号），截至 2023 年 11 月 17 日止，公司向特定对象实际发行 A 股股 ...

Financial Performance - The company's revenue for Q1 2025 was ¥50,467,725.80, representing a 5.33% increase compared to ¥47,915,544.20 in the same period last year[3]. - The net profit attributable to shareholders was -¥45,576,538.97, a decrease of 12.86% from -¥40,381,786.35 year-over-year[3]. - The total operating revenue for the current period is CNY 50,467,725.80, an increase from CNY 47,915,544.20 in the previous period, representing a growth of approximately 5.5%[24]. - The net profit for the current period is -45,576,538.97, compared to -40,380,236.63 in the previous period, indicating a decline of approximately 12.5%[25]. - The total comprehensive income for the current period is -45,593,839.33, compared to -40,355,707.49 in the previous period, reflecting a decrease of about 13.5%[25]. - The basic and diluted earnings per share for the current period are both -0.0465, compared to -0.0412 in the previous period, indicating a worsening of approximately 8.0%[26]. Cash Flow and Assets - The net cash flow from operating activities improved by 34.66%, reaching -¥65,632,343.86 compared to -¥100,443,543.19 in the previous year[3]. - The company's cash and cash equivalents decreased to CNY 365,780,927.32 from CNY 451,840,676.26, a decline of about 19%[20]. - Cash and cash equivalents at the end of the period stand at 351,391,328.46, down from 816,969,617.12 at the end of the previous period, a decrease of about 56.9%[27]. - The operating cash flow for the current period is -65,632,343.86, an improvement from -100,443,543.19 in the previous period, showing a reduction in cash outflow by approximately 34.7%[26]. Assets and Liabilities - Total assets decreased by 3.35% to ¥1,992,785,005.50 from ¥2,061,938,679.96 at the end of the previous year[3]. - The total assets of the company as of March 31, 2025, are CNY 1,992,785,005.50, down from CNY 2,061,938,679.96 at the beginning of the period, reflecting a decrease of approximately 3.3%[22]. - The total liabilities decreased to CNY 632,772,661.63 from CNY 656,332,496.76, a reduction of about 3.6%[22]. - The company's total equity decreased to CNY 1,360,012,343.87 from CNY 1,405,606,183.20, indicating a decline of approximately 3.2%[22]. Investments and Expenses - Investment income surged by 212.51% to ¥4,320,158.46, attributed to the growth in net profits of joint ventures and interest income from large bank deposits[8]. - The total operating costs for the current period amount to CNY 101,542,262.28, up from CNY 90,887,714.68 in the previous period, indicating an increase of about 11.5%[24]. - Sales expenses increased by 35.28% to ¥14,923,130.53, reflecting higher investments in market development and sales personnel costs[8]. - The company incurred credit impairment losses of 3,398,061.31, which is significantly higher than 1,795,408.37 in the previous period, marking an increase of approximately 89.2%[25]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 70,199[10]. - The largest shareholder, China Oceanwide Holdings Group Co., Ltd., holds 24.02% of the shares, totaling 235,702,593 shares[10]. Corporate Governance - The company appointed Mr. Zhang Zhenhua as the vice president, effective immediately upon board approval[14]. - The company held a board meeting to elect candidates for the twelfth board of directors, including both independent and non-independent directors[15]. - The company has elected a new employee representative supervisor, Ms. Xia Kun, to join the newly formed 12th Supervisory Board[17]. - The company has proposed the nomination of two shareholder representative supervisors for the 12th Supervisory Board, pending approval[16]. - The company approved the repurchase and cancellation of 125,800 restricted stocks due to three individuals no longer meeting incentive conditions[13]. Organizational Changes - The company restructured its organization by dissolving the PBG Data R&D Department and establishing an AI Center to oversee AI infrastructure development[14]. - The company decided to continue using RMB 450 million of temporarily idle raised funds for cash management until January 28, 2026[13].

Financial Performance - The company's operating revenue for 2024 was CNY 356,896,420.31, representing an increase of 8.11% compared to CNY 330,126,718.06 in 2023[19]. - The net profit attributable to shareholders for 2024 was a loss of CNY 10,375,438.31, an improvement of 87.00% from a loss of CNY 79,791,984.63 in 2023[19]. - The net cash flow from operating activities improved to a negative CNY 82,489,277.85 in 2024, a 19.30% increase from a negative CNY 102,215,067.80 in 2023[19]. - The basic earnings per share for 2024 was -0.0106, showing an improvement of 87.90% from -0.0876 in 2023[19]. - Total assets at the end of 2024 were CNY 2,061,938,679.96, a 5.66% increase from CNY 1,951,543,466.24 at the end of 2023[19]. - The net assets attributable to shareholders decreased by 1.03% to CNY 1,405,606,183.20 at the end of 2024 from CNY 1,420,251,225.49 at the end of 2023[19]. - The company has reported a decrease in net profit after deducting non-recurring gains and losses, with a loss of CNY 151,674,390.39 in 2024 compared to a loss of CNY 115,760,381.59 in 2023, a decline of 31.02%[19]. Cash Flow and Investment - The company reported a significant difference between net cash flow from operating activities and net profit, with a net cash flow of -¥82,489,277.85 and a net profit of -¥11,466,500[83]. - Investment income amounted to ¥143,019,379.11, representing 1,223.17% of total profit, primarily from equity investment disposals and equity method accounting for joint ventures[85]. - Fair value changes resulted in a gain of ¥6,340,000.00, accounting for 54.22% of total profit, mainly from the fair value changes of held financial assets[85]. - Cash and cash equivalents decreased by 25.65% to ¥451,840,676.26, down from ¥928,057,174.89, due to cash management of temporarily idle raised funds[87]. - The company raised a total of RMB 794,483,087.84 through the issuance of 80,413,268 shares at a price of RMB 9.88 per share[97]. - The company has not yet utilized the remaining funds for temporary liquidity support, which are currently held in a demand deposit account[98]. Digital Healthcare Initiatives - The company is focused on digital healthcare, emphasizing the integration of AI and big data in its services to enhance medical insurance fund management and healthcare quality[30]. - The digital medical insurance business aims to provide standardized and intelligent support systems for medical insurance payment and supervision, enhancing the efficiency of fund utilization[30]. - The company is actively involved in the development of a multi-level medical security system, aligning with national healthcare reforms to improve service delivery[29]. - The introduction of DRG payment services is designed to optimize the payment process for medical institutions, promoting better resource allocation and efficiency[31]. - The company is leveraging AI and big data to establish a disease classification system that supports local healthcare needs and enhances payment accuracy[32]. Research and Development - The company is focusing on upgrading its R&D center, which includes the first and second phases of data platform upgrades, aiming to enhance AI-based medical knowledge graphs and support various business R&D efforts[76]. - The number of R&D personnel decreased by 25.35% from 651 in 2023 to 486 in 2024[77]. - R&D investment amount decreased by 39.16% from ¥49,062,327.32 in 2023 to ¥29,849,857.42 in 2024[78]. - The proportion of R&D investment to operating revenue fell by 6.50% from 14.86% in 2023 to 8.36% in 2024[78]. Corporate Governance and Management Changes - The company has a complete and independent organizational structure, ensuring no mixed operations with controlling shareholders[126]. - The company appointed Yuan Hongquan as the new General Manager on April 25, 2024, after he transitioned from the position of Deputy General Manager[131]. - The company experienced a management change with the resignation of several executives, including Sun Di Cao and Sun Li Qun, due to personal reasons[131]. - The company’s board of directors held a meeting on April 25, 2024, to approve the management changes and discuss future strategies[131]. - The company has engaged in multiple investor communications throughout 2024 to discuss overall performance and future business plans[117]. Environmental and Social Responsibility - The company has published its 2024 ESG report detailing its social responsibility initiatives[173]. - The company is not classified as a key pollutant discharge unit by environmental protection authorities[171]. - No administrative penalties were imposed on the company or its subsidiaries for environmental issues during the reporting period[171]. - The company has taken measures to reduce carbon emissions, although specific details were not disclosed[172]. Market Expansion and Strategic Focus - The company has identified key areas for market expansion, particularly in health services, aiming for a 20.7% growth in this segment[101]. - The company is exploring potential acquisitions to enhance its service offerings and market presence, with a focus on strategic partnerships[101]. - The company aims to transform into a leading health data service provider by leveraging information technology, digitalization, and AI models to enhance customer value[112]. - The strategic focus includes implementing a "smart innovation" strategy to become a data-driven enterprise in the healthcare sector, particularly in the "three medical" fields[112]. Financial Management and Compliance - The company has established a financial service agreement with Guoxin Group Financial Co., Ltd. to handle daily fund settlements, deposits, and loans, which was approved in the board meeting on May 21, 2024[198]. - The maximum daily deposit limit with Guoxin Group Financial Co., Ltd. is RMB 50 million, with an interest rate of 0.525%[195]. - The company has not engaged in any significant related party transactions during the reporting period[191]. - The company has not experienced any major litigation or arbitration matters during the reporting period[189].

监事会对公司 2024 年度内部控制评价报告的意见 根据《企业内部控制基本规范》等有关文件的要求，作为公司监事，本着谨 慎的原则，我们对公司《2024 年度内部控制评价报告》进行了审阅，发表意见 如下： 《2024 年度内部控制评价报告》的形式、内容符合有关法律、法规、规范 性文件的要求，报告真实、准确、完整地反映了公司 2024 年度内部控制的实际 情况，公司内部控制保证了公司经营的合法、合规及公司内部规章制度的贯彻执 行。2024 年，公司未有违反《企业内部控制应用指引》及公司内部控制制度的 情形发生。监事会对公司《2024 年度内部控制评价报告》不存在异议。 国新健康保障服务集团股份有限公司 监 事 会 二零二五年四月二十四日 国新健康保障服务集团股份有限公司 ...

证券简称：国新健康 证券代码：000503 编号：2025-20 国新健康保障服务集团股份有限公司 第十一届监事会第二十八次会议暨2024年度会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国新健康保障服务集团股份有限公司（以下简称"公司"）第十一届监事 会第二十八次会议暨2024年度会议于2025年4月11日发出会议通知，会议由监事 会主席周蔚女士召集并主持，于2025年4月23日以现场结合通讯方式召开。本次 会议应出席监事3人，实际出席监事3人。会议的召开符合有关法律、行政法规、 部门规章和《公司章程》规定。 本次会议以记名投票方式表决，审议通过了如下议案： 一、公司 2024 年年度报告及摘要 经审核，监事会认为董事会编制和审议公司 2024 年年度报告的程序符合法 律、行政法规、中国证监会和深圳证券交易所的相关规定，报告内容能够真实、 准确、完整地反映上市公司的实际情况，不存在任何虚假记载、误导性陈述或 者重大遗漏。 表决结果：3 票赞成，0 票反对，0 票弃权。 本议案尚需提交公司股东大会审议。 具体内容详见同日在巨潮资讯网（网址：ww ...

证券简称：国新健康 证券代码：000503 编号：2025-19 国新健康保障服务集团股份有限公司 第十一届董事会第三十八次会议暨2024年度会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国新健康保障服务集团股份有限公司（以下简称"公司"）第十一届董事 会第三十八次会议暨 2024 年度会议于 2025 年 4 月 11 日发出会议通知，会议由 董事长李永华先生召集并主持，于 2025 年 4月 23 日以现场结合通讯方式召开。 本次会议应出席董事 8 人，实际出席董事 8 人，公司监事和高级管理人员列席 会议。会议的召开符合有关法律、行政法规、部门规章和《公司章程》规定。 本次会议以记名投票方式表决，审议通过了如下议案： 一、公司 2024 年年度报告及摘要 表决结果：8 票赞成，0 票反对，0 票弃权。 本议案尚需提交公司股东大会审议。 具体内容详见同日在巨潮资讯网（网址：www.cninfo.com.cn）披露的 《2024 年年度报告》，以及在《中国证券报》《上海证券报》《证券时报》及 巨潮资讯网（网址：www.cninfo.com.c ...

证券简称：国新健康 证券代码：000503 编号：2025-23 国新健康保障服务集团股份有限公司 关于 2024 年度拟不进行利润分配的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国新健康保障服务集团股份有限公司（以下简称"公司"）于2025年4月23 日召开的第十一届董事会第三十八次会议暨2024年度会议，以8票赞成、0票反对、 0票弃权，审议通过了《公司2024年度利润分配预案》；同日召开的第十一届监 事会第二十八次会议暨2024年度会议，以3票赞成、0票反对、0票弃权，审议通 过了《公司2024年度利润分配预案》，本议案尚需提交公司2024年度股东大会审 议，具体情况如下： 公司连续三个会计年度净利润为负值，不进行现金分红符合相关规定。因此 公司不触及《深圳证券交易所股票上市规则》第 9.8.1 条规定的可能被实施其他 风险警示的情形。 一、利润分配预案基本情况 经中证天通会计师事务所（特殊普通合伙）审计，公司 2024 年度实现归属 于上市公司股东的净利润为-10,375,438.31 元，归属于上市公司股东的扣除非经 常性损益的净利润-1 ...

证券简称：国新健康 证券代码：000503 编号：2025-18 国新健康保障服务集团股份有限公司 关于召开 2025 年第一次临时股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 本次股东大会的议案 1.00 至议案 3.00 采用累积投票方式进行投票，本次应 选非独立董事 6 名，应选独立董事 3 名，应选股东代表监事 2 名。股东所拥有的 选举票数为其所持有表决权的股份数量乘以应选人数，股东可以将所拥有的选 举票数以应选人数为限在议案中任意分配（可以投出零票），但总数不得超过其 拥有的选举票数。 本次股东大会的议案 6.00 需经出席会议的股东所持表决权的三分之二以上 通过，其他议案需经出席会议的股东所持表决权的二分之一以上通过。其中，议 案 6.00，公司限制性股票激励计划（第一期）的激励对象作为关联股东，对该议 案回避表决。 国新健康保障服务集团股份有限公司（以下简称"公司"）于 2025 年 3 月 26 日召开第十一届董事会第三十七次会议，审议通过了《关于召开公司 2025 年 第一次临时股东大会的议案》，公司已于 ...

证券简称：国新健康 证券代码：000503 编号：2025-17 国新健康保障服务集团股份有限公司 关于召开 2025 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2．网络投票时间为：2025 年 5 月 6 日。其中，通过深圳证券交易所交易系 统进行网络投票的具体时间为：2025 年 5 月 6 日 9:15-9:25，9:30-11:30， 13:00- 15:00；通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 5 月 6 日 9:15 至 15:00 期间的任意时间。 1 特别提示： 本次股东大会的议案 1.00 至议案 3.00 采用累积投票方式进行投票，本次应 选非独立董事 6 名，应选独立董事 3 名，应选股东代表监事 2 名。股东所拥有的 选举票数为其所持有表决权的股份数量乘以应选人数，股东可以将所拥有的选 举票数以应选人数为限在的议案中任意分配（可以投出零票），但总数不得超过 其拥有的选举票数。 本次股东大会的议案 6.00 需经出席会议的股东所持表决权的三分之二以上 通过，其他议案需经出席会议 ...

Investment Rating - The report does not explicitly provide an investment rating for the industry or specific stocks Core Insights - The 'national team', represented by Central Huijin, is actively increasing its ETF holdings to stabilize the capital market and rebuild investor confidence, which has positively impacted market sentiment and led to a rebound in the A-share market [2][10][11] - Central Huijin's financial strength and access to liquidity support from the People's Bank of China (PBoC) enable it to significantly increase its market position in extreme scenarios [3][17][20] - The national team's ETF purchases in 2024 reached over RMB 770 billion, indicating a substantial commitment to maintaining market stability [4][33] Summary by Sections National Team's Role - Central Huijin has positioned itself as a "quasi-stabilisation fund" in the capital market, demonstrating its resolve to maintain stability through increased ETF holdings [2][10] - The national team's actions have led to a notable increase in trading volumes of various A-share ETFs since early April 2025 [11][12] Market Impact - The national team's ETF purchases were primarily concentrated in the CSI 300 index, which accounted for 71% of its total net inflow in 2024 [5][10] - The turnover of CSI 500 and CSI 1000 ETFs saw significant increases of 397% and 732% respectively compared to daily averages from the previous year, indicating heightened market activity [5][11] State-Owned Capital Involvement - State-owned capital operation platforms, such as China Chengtong and China Reform, have announced plans to increase their A-share holdings through ETFs, further supporting market stability [21][22] - These platforms are utilizing substantial relending funds (RMB 100 billion and RMB 80 billion respectively) for stock repurchases, indicating a coordinated effort to bolster the market [22][23] Historical Context - The national team's previous interventions, such as in 2015, involved significant market purchases, with aggregate shareholdings exceeding RMB 1.24 trillion, highlighting its historical role in stabilizing the market during downturns [4][39]